Loading company…
Trinomab is a Zhuhai-based biopharmaceutical company, established in 2015, that develops fully native human monoclonal antibody drugs.
Established in 2015 and based in Zhuhai, China, Trinomab researches fully native human monoclonal antibody drugs. Huaxin Liao serves as Chairman and CTO, and Weihong Zheng as CEO and President. TNM002 entered Phase III clinical trials in November 2022, and in April 2023 the company raised about CNY 200 million in strategic investment from new investors including Kangjun Capital and Huajin Securities. Its pipeline covers prevention of respiratory syncytial virus, tetanus, herpes zoster, hCMV and rabies.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in